For instance, VEGF is the key protein in vascular malformations in hereditary hemorrhagic telangiectasia (HHT), where established treatments such as bevacizumab directly target VEGF (Dupuis-Girod et al. 2012; Thompson et al. 2014). Here, VEGFA is linked to vascular malformation.